Published in Eur J Clin Invest on February 01, 2001
Alcohol and acute ischemic stroke onset: the stroke onset study. Stroke (2010) 1.00
Long-term alcohol consumption in relation to all-cause and cardiovascular mortality among survivors of myocardial infarction: the Health Professionals Follow-up Study. Eur Heart J (2012) 0.92
Clotted blood as sign of alcohol intoxication: a retrospective study. Int J Legal Med (2007) 0.75
Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann Intern Med (1993) 3.42
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med (2000) 2.33
Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol (1972) 2.30
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med (1995) 1.93
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
A diagnostic difficulty: two cases of haemophagocytic syndrome in adults. Neth J Med (2009) 1.69
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2012) 1.54
Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost (2003) 1.52
Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A (1977) 1.52
Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood (1995) 1.50
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Factor XI and protection of the fibrin clot against lysis--a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost (1998) 1.43
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost (2001) 1.40
The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors. J Lab Clin Med (1994) 1.40
[Alcohol and coronary disease]. Ned Tijdschr Geneeskd (1996) 1.40
The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion (1992) 1.39
Nonisotopic binding assay for measuring vitamin B12 and folate in serum. Clin Chem (1992) 1.38
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost (2000) 1.32
Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med (1978) 1.30
Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem (1994) 1.27
Inactivation of kallikrein in human plasma. J Clin Invest (1983) 1.27
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med (1978) 1.26
Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res (1974) 1.26
Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost (2001) 1.26
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest (1997) 1.23
Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum (1987) 1.21
Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest (1998) 1.21
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood (1995) 1.16
Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant (2012) 1.16
Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum (1986) 1.15
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis (1983) 1.10
Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry (1980) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet (1999) 1.07
Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. J Clin Invest (1983) 1.05
Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem (1983) 1.04
Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med (1985) 1.04
Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost (1998) 1.03
Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med (1981) 1.02
Iron metabolism and erythropoiesis after surgery. Br J Surg (1998) 1.01
Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest (1988) 1.01
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost (2002) 1.00
Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI. J Biol Chem (1978) 0.99
Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry (1988) 0.99
Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein. J Biol Chem (1980) 0.99
An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature (1979) 0.98
The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem (1988) 0.97
Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J Clin Invest (1978) 0.97
Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. Proc Natl Acad Sci U S A (1990) 0.96
Factor VIII and von Willebrand factor. Thromb Haemost (1998) 0.95
Immunological studies of prekallikrein, kallikrein, and high-molecular-weight kininogen in normal and deficient plasmas and in normal plasma after cold-dependent activation. J Lab Clin Med (1980) 0.94
Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood (2001) 0.94
Aging, physical conditioning, and exercise-induced changes in hemostatic factors and reaction products. J Appl Physiol (1985) (2000) 0.94
The localization of heparin-binding fragments on human C4b-binding protein. J Immunol (1990) 0.94
Probabilistic classification of hemophilia A carriers by discriminant analysis. Thromb Res (1976) 0.93
Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost (1992) 0.92
Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem (1992) 0.92
Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood (1994) 0.92
Organization of the human genes for insulin-like growth factors I and II. FEBS Lett (1986) 0.91
Kinetics of factor VIII-von Willebrand factor association. Blood (1996) 0.91
The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost (2001) 0.90
Human blood platelet factor VIII-related antigen : demonstration of release by alpha-chymotrypsin. Thromb Res (1979) 0.90
The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus. Scand J Rheumatol (1987) 0.90
Binge drinking causes endothelial dysfunction, which is not prevented by wine polyphenols: a small trial in healthy volunteers. Neth J Med (2007) 0.90
Evaluation of the detection rate of hemophilia carriers. Thromb Res (1975) 0.90
Typing of fibrinogen degradation products in urine in various clinical disorders. Scand J Clin Lab Invest (1971) 0.89
The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem (1990) 0.89
Isolation and functional properties of the heavy and light chains of human plasma kallikrein. J Biol Chem (1982) 0.88
Plasma exchange in herpes gestationis. Br Med J (1980) 0.88
Platelet factor VIII-related antigen: immunofluorescent localization. Thromb Res (1978) 0.88
Interaction of human plasma kallikrein and its light chain with C1 inhibitor. Biochemistry (1983) 0.88
Clinical expression of a rare beta-globin gene mutation co-inherited with haemoglobin E-disease. Eur J Clin Chem Clin Biochem (1996) 0.88
Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost (1997) 0.88
Pharmacokinetics of cefepime in patients with respiratory tract infections. Antimicrob Agents Chemother (1990) 0.88
A co-operative study for the detection of the carrier state of classic hemophilia. N Engl J Med (1977) 0.87
The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost (1996) 0.87
The biological half-life of I-131 fibrinogen. Thromb Diath Haemorrh Suppl (1965) 0.87
Identification of different forms of human C4b-binding protein lacking beta-chain and protein S binding ability. Thromb Haemost (1990) 0.87
Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem (1993) 0.87
Studies on components of the contact phase system in patients with advanced gastrointestinal cancer. Cancer (1990) 0.87
Survival of iodine-125-labeled factor VIII in patients with von Willebrand's disease. J Lab Clin Med (1981) 0.87
Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood (1995) 0.87
Reduction of pain on injection caused by propofol. Can J Anaesth (1990) 0.86
Role of plasma kallikrein in the proteolytic activation of the renin-angiotensin system. Clin Exp Hypertens (1980) 0.86
Inhibition of human blood coagulation factor XIa by C-1 inhibitor. Biochemistry (1988) 0.86
Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother (1994) 0.86
Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages. Thromb Haemost (1995) 0.85
Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin. Biochem J (1996) 0.85
von Willebrand factor as a regulator of intrinsic factor X activation. J Lab Clin Med (1994) 0.85
The contact activation mechanism in human plasma: activation induced by dextran sulfate. Blood (1982) 0.85
Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. Biochem J (1998) 0.85